ArticleBMC cancer2024
Optimal timing of chemoradiation after resection or biopsy of glioblastomas: a nationwide population-based study.
Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThis study investigated the optimal timing of concurrent chemoradiotherapy (CCRT) following surgery for patients with newly diagnosed glioblastoma (GBM). The focus was on understanding whether the interval between surgery and CCRT impacts survival outcomes.
methodsData from the Korean National Health Insurance Research Database ( https://opendata.hira.or.kr/ ) were collected to retrospectively review 3,586 patients diagnosed with GBM in South Korea between 2008 and 2021. Patients were divided into early CCRT (≤ 21 days between surgery and CCRT) and late CCRT (> 21 days between surgery and CCRT) groups and further categorised based on the type of surgery (biopsy alone or surgical resection). The study estimated overall survival (OS) and conducted univariable and multivariable Cox regression analyses.
resultsThe median overall survival (OS) for the entire cohort was 19.98 months (95% Confidence Interval [CI]: 19.12-20.86 months). In univariable analysis, the late CCRT group demonstrated a longer median OS compared to the early CCRT group (20.47 vs. 17.94 months, P = 0.0002, log-rank test). However, this difference was not significant in multivariable analysis (Hazard Ratio [HR] = 0.98, 95% CI: 0.782-1.091, P = 0.6663). Subgroup analysis revealed that late CCRT was associated with prolonged OS in patients who underwent surgical resection (adjusted HR = 0.85, 95% CI: 0.752-0.955, P = 0.0065), whereas in the biopsy-alone group, late CCRT was associated with shorter OS (adjusted HR = 1.80, 95% CI: 1.378-2.346, P < 0.0001).
conclusionsPatients who initiated CCRT more than 21 days post-resection demonstrated improved overall survival (OS) compared to those who began CCRT earlier. In contrast, among patients who underwent biopsy alone, initiating CCRT within 21 days was associated with better outcomes. These findings suggest that the optimal timing for CCRT initiation in GBM may depend on the extent of residual tumour.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.